Westfield Capital Management
VRTX icon

Westfield Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Westfield Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
2,189
+1,325
+153% +$587K ﹤0.01% 263
2026
Q1 		$386K Sell
864
-268
-24% -$125K ﹤0.01% 238
2025
Q4 		$513K Buy
+1,132
New +$488K ﹤0.01% 233
2025
Q1 		– Sell
-1,742
Closed -$702K – 279
2024
Q4 		$702K Buy
1,742
+470
+37% +$218K ﹤0.01% 223
2024
Q3 		$592K Buy
1,272
+728
+134% +$350K ﹤0.01% 235
2024
Q2 		$255K Buy
+544
New +$236K ﹤0.01% 247
2021
Q1 		– Sell
-652,910
Closed -$154M – 286
2020
Q4 		$154M Buy
652,910
+56,431
+9% +$12.9M 0.92% 24
2020
Q3 		$162M Buy
596,479
+62,901
+12% +$17.4M 1.05% 19
2020
Q2 		$155M Sell
533,578
-93,912
-15% -$25.5M 1.07% 20
2020
Q1 		$149M Sell
627,490
-90,178
-13% -$20.7M 1.32% 14
2019
Q4 		$157M Sell
717,668
-215,080
-23% -$43.5M 1.12% 21
2019
Q3 		$158M Buy
932,748
+141,428
+18% +$25M 1.27% 18
2019
Q2 		$145M Buy
791,320
+109,094
+16% +$19.1M 1.09% 19
2019
Q1 		$125M Buy
682,226
+39,336
+6% +$7.27M 0.96% 22
2018
Q4 		$107M Buy
642,890
+93,461
+17% +$16.2M 0.91% 22
2018
Q3 		$106M Sell
549,429
-322,427
-37% -$57.4M 0.74% 37
2018
Q2 		$148M Buy
871,856
+94,755
+12% +$14.7M 1.11% 18
2018
Q1 		$127M Buy
777,101
+158,240
+26% +$25.8M 0.98% 23
2017
Q4 		$92.7M Buy
+618,861
New +$91.6M 0.71% 40
2017
Q2 		– Sell
-355,880
Closed -$38.9M – 285
2017
Q1 		$38.9M Buy
+355,880
New +$31.3M 0.33% 106
2016
Q1 		– Sell
-4,495
Closed -$566K – 295
2015
Q4 		$566K Sell
4,495
-1,957,104
-100% -$236M ﹤0.01% 250
2015
Q3 		$204M Buy
1,961,599
+1,750,058
+827% +$225M 1.45% 7
2015
Q2 		$26.1M Buy
211,541
+36,784
+21% +$4.64M 0.16% 165
2015
Q1 		$20.6M Sell
174,757
-109,901
-39% -$13.2M 0.12% 207
2014
Q4 		$33.8M Sell
284,658
-4,228
-1% -$476K 0.2% 150
2014
Q3 		$32.4M Buy
+288,886
New +$27.5M 0.2% 150

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Westfield Capital Management's VRTX Position: Q2 2026 in Review

Westfield Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 153% in Q2 2026, buying an estimated $587K and bringing the position to 2,189 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #263.

Westfield Capital Management first reported a position in VRTX in Q3 2014 and has held it in 26 quarters since. The position peaked at $204M in Q3 2015. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Westfield Capital Management held 2,189 shares of Vertex Pharmaceuticals worth $1.09M as of Q2 2026.
  • Westfield Capital Management bought 1,325 Vertex Pharmaceuticals shares in Q2 2026, an estimated $587K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Westfield Capital Management's portfolio in Q2 2026, its #263 holding.
  • Westfield Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 26 quarters since.
  • Westfield Capital Management's Vertex Pharmaceuticals position peaked at $204M in Q3 2015.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.